Phi Pharma SA is developing a new class of anti-cancer drugs: Peptide Drug Conjugates (PDCs) effective in multiple human cancers using an innovative mechanism of cell entry: novel CSPG4 targeting bio-pharmaceuticals.
Phi Pharma SA is developing a new class of anti-cancer drugs: Peptide Drug Conjugates (PDCs) effective in multiple human cancers using an innovative mechanism of cell entry: novel CSPG4 targeting bio-pharmaceuticals.
Place du Midi 36, 1950 Sion, Switzerland